Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intratumor heterogeneity defines treatment‐resistant HER 2+ breast tumors

22 Aug 2018

Abstract excerpt

Targeted therapy for patients with HER2-positive (HER2+) breast cancer has improved overall survival, but many patients still suffer relapse and death from the disease. Intratumor heterogeneity of both estrogen receptor (ER) and HER2 expression has been proposed to play a key role in treatment failure, but little work has been done to comprehensively study this heterogeneity at the single-cell level. In this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30133130
DOI: 10.1002/1878-0261.12375

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intratumor heterogeneity defines treatment‐resistant HER 2+ breast tumorsPMID 30133130Read ↗

Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumorsSemantic proximity Read ↗

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.Semantic proximity Read ↗

The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer.Semantic proximity Read ↗

High HER2 intratumoral heterogeneity is a predictive factor for poor prognosis in Early-stage and Locally Advanced HER2-positive Breast CancerSemantic proximity Read ↗

Tumor Heterogeneity in Breast CancerSemantic proximity Read ↗

A Case Series Exploration of Multi-Regional Expression Heterogeneity in Triple-Negative Breast Cancer PatientsSemantic proximity Read ↗

Genetic Heterogeneity in HER2 Testing in Breast Cancer: Panel Summary and GuidelinesSemantic proximity Read ↗

Intratumor Heterogeneity: Novel Approaches for Resolving Genomic Architecture and Clonal EvolutionSemantic proximity Read ↗

Single-cell allelic transcriptomic analysis unravels intratumoral gene expression heterogeneity linked to TNBC pathogenesisSemantic proximity Read ↗

Breast Cancer Heterogeneity and Response to Novel TherapeuticsSemantic proximity Read ↗

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapySemantic proximity Read ↗

Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.